ערך בספרים למניה: BrainStorm Cell Therapeutics (BCLI)

The absence of profitable assets and regulatory complexities are creating cash flow stagnation, as confirmed by the actual book value per share; the value of -0.94 reflects this status. Stability is ensured by distributing drug production across external US cGMP centers. Structural flexibility is maintained through the full outsourcing of research and production, which relieves Brainstorm Cell (BCLI) of excessive capital expenditures.

For the biotech sector, where Brainstorm Cell (BCLI) focuses on the NurOwn platform and the approval of ALS therapy, this indicator reflects the actual net asset value available upon business liquidation. By analyzing the historical trend of the book value per share, an investor assesses the gap between the market price and equity minus liabilities, which is critical for risk assessment while awaiting Phase 3 clinical trial results.